Better, Faster, Smaller: Personalized Medicine Could Bring R&D Savings
PHILADELPHIA - One near-term benefit of adopting a personalized medicine approach to drug development would be a lower cost for clinical trials by conducting smaller, faster studies that will produce better results and help companies make go/ no go decisions sooner, according to speakers at the Wharton Health Care Business Conference
You may also be interested in...
Pfizer’s lung cancer drug Xalkori and Roche’s melanoma drug Zelboraf launched last year in tandem with companion diagnostics. But a slow launch trajectory compared to other recent cancer drugs points to pitfalls for marketing a drug to just a subset of patients.
The Predictive Safety Testing Consortium will allow companies to patent safety testing methodologies developed through the collaboration, but firms will be required to grant access to other members
Targeted cancer therapies should be studied in large Phase II programs that incorporate biomarkers, a panelist said at the annual meeting of the American Society of Clinical Oncology in Orlando, Fla